

Utility of Spherical Human Liver Microtissues for Prediction of Clinical Drug-Induced Liver Injury

Proctor, WR², Foster, AJ^{1†}, Vogt, J², Summers, C¹, Middleton, B¹, Pilling, MA¹, Sheinson, D², Kijanska, M³, Ströbel, S³, Haugstetter, J³, Kelm, JM³, Misner, D², Morgan, P¹, Messner, S³, Williams, D¹


¹ Drug Safety and Metabolism, †Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, and Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom

² Investigative Toxicology, Department of Safety Assessment, Genentech, Inc. 1 DNA Way, South San Francisco, CA, 94080, USA

³ InSphero AG, Wagistrasse 27, 8952 Schlieren, Switzerland

†Corresponding author: Alison Foster, Drug Safety and Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom email address: alison.foster2@astrazeneca.com

Supplemental Figure: S1



Supplemental Fig. S1. Exemplary graphs (randomly chosen) of dose-response curves obtained from 2D PHH (●) and 3D hLiMT (■). Four compounds are displayed from each DILI-severity category.